NR
NRXS.US Neuraxis, Inc.
- Market cap
- USD 68.1M
- P/E
- -
- P/B
- 21.26x
- ROE
- -389.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NRXS.US undervalued?
Graham numberThe Graham number of Neuraxis, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Neuraxis, Inc. fundamental analysis
No fundamental analysis for Neuraxis, Inc. yet.
Neuraxis, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Neuraxis, Inc.
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal…
Full company profileNeuraxis, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Neuraxis, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 1.93M | 2.72M | 2.68M | 2.46M | 2.69M | 3.57M | 7.42M |
| Gross Profit | 1.45M | 2.25M | 2.39M | 2.16M | 2.32M | 3.01M | 6.40M |
| Operating Income | -4.12M | -2.97M | -3.37M | -6.66M | -7.16M | -7.83M | -13.9M |
| EBITDA | -3.61M | -2.95M | -4.33M | -9.23M | -7.90M | -7.67M | -13.7M |
| Net Income | -3.73M | -3.03M | -4.78M | -14.6M | -8.24M | -7.80M | -14.1M |
| EPS | -0.69 | -0.56 | -0.57 | -2.32 | -1.19 | -0.86 | -1.09 |
| Balance Sheet | |||||||
| Total Assets | 2.79M | 760K | 1.48M | 509K | 4.76M | 6.40M | 6.66M |
| Total Liabilities | 1.15M | 1.59M | 7.05M | 1.91M | 2.69M | 3.00M | 3.03M |
| Shareholders' Equity | 1.64M | -826K | -5.57M | -1.40M | 2.07M | 3.40M | 3.62M |
| Cash & Short-term Investments | 1.90M | 321K | 254K | 78.6K | 3.70M | 4.97M | 4.48M |
| Total Debt | 311K | 439K | 599K | 224K | 473K | 417K | 352K |
| Cash Flow | |||||||
| Operating Cash Flow | -4.14M | -2.23M | -2.30M | -6.69M | -6.10M | -6.43M | -6.04M |
| Capital Expenditure | 27.7K | 1.39K | 61.2K | 71.8K | 27.8K | 31.2K | 8.41K |
| Free Cash Flow | -4.17M | -2.24M | -2.36M | -6.77M | -6.13M | -6.46M | -6.05M |
| Ratios | |||||||
| ROE | -226.7% | - | - | - | -398.6% | -229.5% | -389.6% |
| ROA | -133.6% | -398.2% | -322.8% | -2,870.8% | -173.2% | -121.8% | -212.1% |
| Net Profit Margin | -193.0% | -111.3% | -178.0% | -594.6% | -306.8% | -218.5% | -190.2% |
| Debt to Equity | 0.19x | - | - | - | 0.23x | 0.12x | 0.10x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Neuraxis, Inc. dividends
Neuraxis, Inc. has not paid dividends in the last 6 fiscal years.
Who owns Neuraxis, Inc.
- Insiders 25.36%
- Institutions 28.84%
- Public & others 45.80%
- Shares outstanding 14.2M
- Free float 8.33M
Neuraxis, Inc. company profile
- Company name
- Neuraxis, Inc.
- Ticker
- NRXS.US
- Exchange
- USA Stocks
- Listed since
- Aug 9, 2023
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 24
- Fiscal year end
- December
- Address
- 11611 North Meridian St, Carmel, IN, United States, 46032
- Phone
- 812 689 0791
- Website
- neuraxis.com
About Neuraxis, Inc.
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.
Neuraxis, Inc. management
9- Mr. Brian CarricoPresident, CEO & Director · born 1982
- Mr. Timothy Robert HenrichsChief Financial Officer · born 1973
- Dr. Adrian MirandaSenior VP of Science & Technology and Chief Medical Officer · born 1970
- Dr. Thomas CarricoChief Regulatory Officer and Compliance & Privacy Officer · born 1957
- Dr. Christopher Robin Brown D.D.S.Founder, Director of Innovation & Director · born 1954
- Ryan KuhlmanVice President of Sales
- Ms. Trisha BaumgardtVice President of Marketing
- Mr. Craig BlanchardChief Commercial Officer
- Mr. Behnam Shamsian CPAInvestor Relations